Expression data from renal cancer patient-derived xenograft tumor treated with temsirolimus or vehicle

We kept 2 types of primary xenograft models (KURC;Kyoto University Renal Cancer-1,3) derived from human renal cell carcinoma tissues, and 10 mg/kg of temsirolimus or vehicle was intraperitoneally administered.We performed microarray analysis to compare the gene expression profile of temsirolimus-treated primary xenograft tumors with that of vehicle-treated. Total RNA was extracted from KURC1,3 xenograft tumors treated with temsirolimus or vehicle. Ten mg/kg of temsirolimus was intraperitoneally administered once a week, and KURC1 kept sensitive and KURC3 developed resistance to temsirolimus.